In addition to selective RET inhibition for the treatment of patients with RET alterations, inhibitors of NTRK fusions (tropomyosin receptor kinase [TRK] inhibitors) and BRAF mutations (BRAF inhibitors) have either been approved or have shown promising activity in thyroid cancer (88, 89). Here, NTRK1 is linked to thyroid gland carcinoma.